Calcimedica

Developer of CRAC channel inhibitor drugs for inflammatory diseases

placeSan Diego, California, United States calendar_todayFounded 2006 groups11 employees language calcimedica.com

Registered entities

Innovation

35 patent families (21 granted) — focus: Chemistry & metallurgy, Human necessities, Physics & computing; filing pace slowing. Cited 7,322 times.

YearFilings
20157
20169
20178
20188
20196
20206
20215
20226
20236
20246
20252
20263

Investor mix

13 investors on record; lead investors include Valence Life Sciences, Sanderling Ventures, SR One, Biogen.

Investor typeCountShare
Venture capital1077%
Private equity18%
Other / undisclosed215%
Coming soon